Multi-modality management of craniopharyngioma: A review of various treatments and their outcomes

John Varlotto, Christopher DiMaio, Clemens Grassberger, Matthew Tangel, Heath Mackley, Matt Pavelic, Charles Specht, Steven Sogge, Dan Thach Nguyen, Michael Glantz, Cheng Saw, Urvashi Upadhyay, Richard Moser, Shakeeb Yunus, Paul Rava, Thomas Fitzgerald, Jonathan Glanzman, Jonas Sheehan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Craniopharyngioma is a rare tumor that is expected to occur in 400 patients/year in the United States. While surgical resection is considered to be the primary treatment when a patient presents with a craniopharyngioma, only 30% of such tumors present in locations that permit complete resection. Radiotherapy has been used as both primary and adjuvant therapy in the treatment of craniopharyngiomas for over 50 years. Modern radiotherapeutic techniques, via the use of CT-based treatment planning and MRI fusion, have permitted tighter treatment volumes that allow for better tumor control while limiting complications. Modern radiotherapeutic series have shown high control rates with lower doses than traditionally used in the two-dimensional treatment era. Intracavitary radiotherapy with radio-isotopes and stereotactic radiosurgery may have a role in the treatment of recurrent cystic and solid recurrences, respectively. Recently, due to the exclusive expression of the Beta-catenin clonal mutations and the exclusive expression of BRAF V600E clonal mutations in the overwhelming majority of adamantinomatous and papillary tumors respectively, it is felt that inhibitors of each pathway may play a role in the future treatment of these rare tumors.

Original languageEnglish (US)
Pages (from-to)173-187
Number of pages15
JournalNeuro-Oncology Practice
Volume3
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Craniopharyngioma
Therapeutics
Neoplasms
Radiotherapy
Mutation
Radiosurgery
beta Catenin
Radio
Isotopes
Recurrence

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)

Cite this

Varlotto, John ; DiMaio, Christopher ; Grassberger, Clemens ; Tangel, Matthew ; Mackley, Heath ; Pavelic, Matt ; Specht, Charles ; Sogge, Steven ; Nguyen, Dan Thach ; Glantz, Michael ; Saw, Cheng ; Upadhyay, Urvashi ; Moser, Richard ; Yunus, Shakeeb ; Rava, Paul ; Fitzgerald, Thomas ; Glanzman, Jonathan ; Sheehan, Jonas. / Multi-modality management of craniopharyngioma : A review of various treatments and their outcomes. In: Neuro-Oncology Practice. 2016 ; Vol. 3, No. 3. pp. 173-187.
@article{b03ea8159c9f4f4c9fe2c272c5ad398e,
title = "Multi-modality management of craniopharyngioma: A review of various treatments and their outcomes",
abstract = "Craniopharyngioma is a rare tumor that is expected to occur in 400 patients/year in the United States. While surgical resection is considered to be the primary treatment when a patient presents with a craniopharyngioma, only 30{\%} of such tumors present in locations that permit complete resection. Radiotherapy has been used as both primary and adjuvant therapy in the treatment of craniopharyngiomas for over 50 years. Modern radiotherapeutic techniques, via the use of CT-based treatment planning and MRI fusion, have permitted tighter treatment volumes that allow for better tumor control while limiting complications. Modern radiotherapeutic series have shown high control rates with lower doses than traditionally used in the two-dimensional treatment era. Intracavitary radiotherapy with radio-isotopes and stereotactic radiosurgery may have a role in the treatment of recurrent cystic and solid recurrences, respectively. Recently, due to the exclusive expression of the Beta-catenin clonal mutations and the exclusive expression of BRAF V600E clonal mutations in the overwhelming majority of adamantinomatous and papillary tumors respectively, it is felt that inhibitors of each pathway may play a role in the future treatment of these rare tumors.",
author = "John Varlotto and Christopher DiMaio and Clemens Grassberger and Matthew Tangel and Heath Mackley and Matt Pavelic and Charles Specht and Steven Sogge and Nguyen, {Dan Thach} and Michael Glantz and Cheng Saw and Urvashi Upadhyay and Richard Moser and Shakeeb Yunus and Paul Rava and Thomas Fitzgerald and Jonathan Glanzman and Jonas Sheehan",
year = "2016",
month = "9",
day = "1",
doi = "10.1093/nop/npv029",
language = "English (US)",
volume = "3",
pages = "173--187",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "3",

}

Varlotto, J, DiMaio, C, Grassberger, C, Tangel, M, Mackley, H, Pavelic, M, Specht, C, Sogge, S, Nguyen, DT, Glantz, M, Saw, C, Upadhyay, U, Moser, R, Yunus, S, Rava, P, Fitzgerald, T, Glanzman, J & Sheehan, J 2016, 'Multi-modality management of craniopharyngioma: A review of various treatments and their outcomes', Neuro-Oncology Practice, vol. 3, no. 3, pp. 173-187. https://doi.org/10.1093/nop/npv029

Multi-modality management of craniopharyngioma : A review of various treatments and their outcomes. / Varlotto, John; DiMaio, Christopher; Grassberger, Clemens; Tangel, Matthew; Mackley, Heath; Pavelic, Matt; Specht, Charles; Sogge, Steven; Nguyen, Dan Thach; Glantz, Michael; Saw, Cheng; Upadhyay, Urvashi; Moser, Richard; Yunus, Shakeeb; Rava, Paul; Fitzgerald, Thomas; Glanzman, Jonathan; Sheehan, Jonas.

In: Neuro-Oncology Practice, Vol. 3, No. 3, 01.09.2016, p. 173-187.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multi-modality management of craniopharyngioma

T2 - A review of various treatments and their outcomes

AU - Varlotto, John

AU - DiMaio, Christopher

AU - Grassberger, Clemens

AU - Tangel, Matthew

AU - Mackley, Heath

AU - Pavelic, Matt

AU - Specht, Charles

AU - Sogge, Steven

AU - Nguyen, Dan Thach

AU - Glantz, Michael

AU - Saw, Cheng

AU - Upadhyay, Urvashi

AU - Moser, Richard

AU - Yunus, Shakeeb

AU - Rava, Paul

AU - Fitzgerald, Thomas

AU - Glanzman, Jonathan

AU - Sheehan, Jonas

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Craniopharyngioma is a rare tumor that is expected to occur in 400 patients/year in the United States. While surgical resection is considered to be the primary treatment when a patient presents with a craniopharyngioma, only 30% of such tumors present in locations that permit complete resection. Radiotherapy has been used as both primary and adjuvant therapy in the treatment of craniopharyngiomas for over 50 years. Modern radiotherapeutic techniques, via the use of CT-based treatment planning and MRI fusion, have permitted tighter treatment volumes that allow for better tumor control while limiting complications. Modern radiotherapeutic series have shown high control rates with lower doses than traditionally used in the two-dimensional treatment era. Intracavitary radiotherapy with radio-isotopes and stereotactic radiosurgery may have a role in the treatment of recurrent cystic and solid recurrences, respectively. Recently, due to the exclusive expression of the Beta-catenin clonal mutations and the exclusive expression of BRAF V600E clonal mutations in the overwhelming majority of adamantinomatous and papillary tumors respectively, it is felt that inhibitors of each pathway may play a role in the future treatment of these rare tumors.

AB - Craniopharyngioma is a rare tumor that is expected to occur in 400 patients/year in the United States. While surgical resection is considered to be the primary treatment when a patient presents with a craniopharyngioma, only 30% of such tumors present in locations that permit complete resection. Radiotherapy has been used as both primary and adjuvant therapy in the treatment of craniopharyngiomas for over 50 years. Modern radiotherapeutic techniques, via the use of CT-based treatment planning and MRI fusion, have permitted tighter treatment volumes that allow for better tumor control while limiting complications. Modern radiotherapeutic series have shown high control rates with lower doses than traditionally used in the two-dimensional treatment era. Intracavitary radiotherapy with radio-isotopes and stereotactic radiosurgery may have a role in the treatment of recurrent cystic and solid recurrences, respectively. Recently, due to the exclusive expression of the Beta-catenin clonal mutations and the exclusive expression of BRAF V600E clonal mutations in the overwhelming majority of adamantinomatous and papillary tumors respectively, it is felt that inhibitors of each pathway may play a role in the future treatment of these rare tumors.

UR - http://www.scopus.com/inward/record.url?scp=85043624914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043624914&partnerID=8YFLogxK

U2 - 10.1093/nop/npv029

DO - 10.1093/nop/npv029

M3 - Article

AN - SCOPUS:85043624914

VL - 3

SP - 173

EP - 187

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 3

ER -